Jean-Luc Herbeaux Appointed CEO of CordenPharma
Jean-Luc Herbeaux has been appointed as the new CEO of CordenPharma, effective October 1, 2026. He succeeds Michael Quirmbach, who will transition to the board as a senior advisor.
CordenPharma has appointed Dr. Jean-Luc Herbeaux as the company's new Chief Executive Officer. The appointment will take effect on October 1, 2026. Dr. Herbeaux will lead the company through its next phase of growth. The current CEO, Dr. Michael Quirmbach, will step down from his executive role to become a member of the Board of Directors and a Senior Advisor, continuing his involvement with the company.
With this leadership transition, CordenPharma aims to strengthen its position as a contract development and manufacturing organization (CDMO) within the pharmaceutical sector. Dr. Herbeaux is expected to bring strategic direction and extensive experience to the company's development. His prior career includes executive positions at international pharmaceutical firms.
CordenPharma specializes in the manufacturing of peptides, lipids, and other complex molecules for the pharmaceutical industry. The company provides services ranging from early-stage development to commercial production. Under Dr. Herbeaux's leadership, the company seeks to expand its capabilities, particularly in specialized active pharmaceutical ingredients and high-value services.
Dr. Quirmbach's transition to the board and advisory role ensures continuity and leverages his experience during the leadership change. His long-standing tenure with CordenPharma is considered valuable for the company's strategic decision-making.